{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:24:35Z","timestamp":1793831075833,"version":"4.6.1"},"reference-count":56,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.bbmt.2020.01.013","type":"journal-article","created":{"date-parts":[[2020,1,28]],"date-time":"2020-01-28T02:37:33Z","timestamp":1580179053000},"page":"1179-1188","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":72,"title":["Infections after Allogenic Transplant with Post-Transplant Cyclophosphamide: Impact of Donor HLA Matching"],"prefix":"10.1016","volume":"26","author":[{"given":"Chiara","family":"Oltolini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaella","family":"Greco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Galli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Clerici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Lorentino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Teresa","family":"Lupo Stanghellini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Giglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Uhr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6380-0377","authenticated-orcid":false,"given":"Marco","family":"Ripa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Scarpellini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1334-0851","authenticated-orcid":false,"given":"Massimo","family":"Bernardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Consuelo","family":"Corti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacopo","family":"Peccatori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Castagna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Ciceri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2020.01.013_bib0001","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1038\/s41409-018-0153-1","article-title":"Is the use of unrelated donor transplantation leveling off in Europe? The 2016 European Society for Blood and Marrow Transplant activity survey report","volume":"53","author":"Passweg","year":"2018","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.01.013_bib0002","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1038\/s41409-019-0516-2","article-title":"Indications for hematopoietic stem cell transplantation for haematological diseases, solid tumors and immune disorders: current practice in Europe, 2019","volume":"54","author":"Duarte","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.01.013_bib0003","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1182\/blood-2015-04-639831","article-title":"Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia","volume":"126","author":"Ciurea","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.01.013_bib0004","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1080\/17474086.2017.1318054","article-title":"Post-transplant cyclophosphamide, a promising anti-graft versus host disease prophylaxis: where do we stand?","volume":"10","author":"Mussetti","year":"2017","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.bbmt.2020.01.013_bib0005","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","article-title":"HLA-haploidentical bone marrow transplantation for hematologic malignancies using non-myeloablative conditioning and high-dose, post transplantation cyclophosphamide","volume":"14","author":"Luznik","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.01.013_bib0006","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.bbmt.2014.03.003","article-title":"Peripheral blood hematopoietic stem cells for transplantation of hematological diseases from related, haploidentical donors after reduced-intensity conditioning","volume":"20","author":"Raj","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.01.013_bib0007","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1038\/bmt.2014.108","article-title":"Haploidentical transplantation using G-CSF-mobilized T-cell replete PBSCs and post-transplantation CY after non-myeloablative conditioning is safe and is associated with favorable outcomes","volume":"49","author":"Bhamidipati","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.01.013_bib0008","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.bbmt.2014.02.001","article-title":"Bone marrow compared with peripheral blood stem cells for haploidentical transplantation with a nonmyeloablative conditioning regimen and post-transplantation cyclophosphamide","volume":"20","author":"Castagna","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.01.013_bib0009","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.bbmt.2012.08.014","article-title":"Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning","volume":"19","author":"Raiola","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.01.013_bib0010","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1182\/blood-2016-06-723205","article-title":"Post-transplantation cyclophosphamide and sirolimus for prevention of GVHD after HLA-matched PBSC transplantation","volume":"128","author":"Greco","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.01.013_bib0011","doi-asserted-by":"crossref","first-page":"401","DOI":"10.3324\/haematol.2016.151779","article-title":"Post-transplant cyclophosphamide versus anti-thymocyte globulin as graft- versus-host disease prophylaxis in haploidentical transplant","volume":"102","author":"Ruggeri","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2020.01.013_bib0012","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1086\/322604","article-title":"Evolution, incidence, and susceptibility of bacterial bloodstream isolates from 519 bone marrow transplant patients","volume":"33","author":"Collin","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.bbmt.2020.01.013_bib0013","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1038\/bmt.2014.37","article-title":"Etiology, clinical features and outcomes of pre-engraftment and post-engraftment bloodstream infection in hematopoietic SCT recipients","volume":"49","author":"Gudiol","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.01.013_bib0014","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.bbmt.2008.10.024","article-title":"Blood stream infections in allogeneic hematopoietic stem cell transplant recipients: reemergence of Gram-negative rods and increasing antibiotic resistance","volume":"15","author":"Mikulska","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.01.013_bib0015","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/tid.12175","article-title":"Incidence, risk factors, and outcome of bloodstream infections during the pre-engraftment phase in 521 allogeneic hematopoietic stem cell transplantations","volume":"16","author":"Blennow","year":"2014","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.bbmt.2020.01.013_bib0016","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/tid.12345","article-title":"Risk factors for pre- and post-engraftment bloodstream infections after allogeneic hematopoietic stem cell transplantation","volume":"17","author":"Kikuchi","year":"2015","journal-title":"Transpl Infect Dis"},{"issue":"1","key":"10.1016\/j.bbmt.2020.01.013_bib0017","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s00277-016-2828-2","article-title":"Pre-engraftment bloodstream infections in acute leukemia patients undergoing unrelated cord blood transplantation following intensified myeloablative conditioning without ATG","volume":"96","author":"Zheng","year":"2016","journal-title":"Ann Hematol"},{"key":"10.1016\/j.bbmt.2020.01.013_bib0018","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/bmt.2014.231","article-title":"Infections by carbapenem-resistant Klebsiella pneumoniae in SCT recipients: a nationwide retrospective survey from Italy","volume":"50","author":"Girmenia","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.01.013_bib0019","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.3324\/haematol.2013.091025","article-title":"European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia","volume":"98","author":"Averbuch","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2020.01.013_bib0020","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/tid.12365","article-title":"Infections after T-replete haploidentical transplantation and high-dose cyclophosphamide as graft-versus-host disease prophylaxis","volume":"17","author":"Crocchiolo","year":"2015","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.bbmt.2020.01.013_bib0021","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1016\/j.bbmt.2015.04.025","article-title":"Post-transplantation cyclophosphamide and sirolimus after haploidentical hematopoietic stem cell transplantation using a treosulfan-based myeloablative conditioning and peripheral blood stem cells","volume":"21","author":"Cieri","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.01.013_bib0022","doi-asserted-by":"crossref","DOI":"10.1111\/tid.12629","article-title":"Epidemiology of infections following haploidentical peripheral blood hematopoietic cell transplantation","volume":"19","author":"Slade","year":"2017","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.bbmt.2020.01.013_bib0023","doi-asserted-by":"crossref","first-page":"e64","DOI":"10.1111\/bjh.16189","article-title":"Infectious complications after post-transplantation cyclophosphamide and anti-thymocyte globulin-based haploidentical stem cell transplantation","volume":"187","author":"Mohty","year":"2019","journal-title":"Br J Hematol"},{"key":"10.1016\/j.bbmt.2020.01.013_bib0024","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/j.bbmt.2012.07.003","article-title":"Improved early outcomes using a T cell replete graft compared with t cell depleted haploidentical hematopoietic stem cell transplantation","volume":"18","author":"Ciurea","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.01.013_bib0025","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.bbmt.2015.09.001","article-title":"International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the Mount Sinai Acute GVHD International Consortium","volume":"22","author":"Harris","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.01.013_bib0026","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.bbmt.2020.01.013_bib0027","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.hoc.2010.11.011","article-title":"Cytomegalovirus in hematopoietic stem cell transplant recipients","volume":"25","author":"Ljungman","year":"2011","journal-title":"Hematol Oncol Clin North Am"},{"issue":"23","key":"10.1016\/j.bbmt.2020.01.013_bib0028","doi-asserted-by":"crossref","first-page":"5711","DOI":"10.1182\/blood-2008-10-143560","article-title":"How we treat cytomegalovirus in hematopoietic cell transplant recipients","volume":"113","author":"Boeckh","year":"2009","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bbmt.2020.01.013_bib0029","first-page":"78","article-title":"Risk factors for the development of cytomegalovirus disease after allogeneic stem cell transplantation","volume":"91","author":"Ljungman","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2020.01.013_bib0030","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","article-title":"Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation","volume":"377","author":"Marty","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2020.01.013_bib0031","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/cid\/ciw668","article-title":"Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials","volume":"64","author":"Ljungman","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.bbmt.2020.01.013_bib0032","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/bmt.2008.162","article-title":"Management of CMV, HHV-6, HHV-7 and Kaposi-sarcoma herpesvirus (HHV-8) infections in patients with hematological malignancies and after SCT","volume":"42","author":"Ljungman","year":"2008","journal-title":"Bone Marrow Transplantation"},{"key":"10.1016\/j.bbmt.2020.01.013_bib0033","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1007\/s11908-014-0416-y","article-title":"Adenovirus: current epidemiology and emerging approaches to prevention and treatment","volume":"16","author":"Sandkovsky","year":"2014","journal-title":"Curr Infect Dis Rep"},{"key":"10.1016\/j.bbmt.2020.01.013_bib0034","first-page":"12","article-title":"ECIL guidelines for the prevention, diagnosis and treatment of BK polyomavirus-associated hemorrhagic cystitis in hematopoietic stem cell transplant recipients","volume":"73","author":"Cesaro","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.bbmt.2020.01.013_bib0035","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/bmt.2008.386","article-title":"Management of HSV, VZV, EBV infections in patients with hematological malignancies and after SCT: guidelines from the Second European Conference on Infections in Leukemia","volume":"43","author":"Styczynski","year":"2009","journal-title":"Bone Marrow Transplantation"},{"key":"10.1016\/j.bbmt.2020.01.013_bib0036","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1086\/588660","volume":"46","author":"De Pauw","year":"2008","journal-title":"Clin Infect Dis"},{"issue":"19","key":"10.1016\/j.bbmt.2020.01.013_bib0037","doi-asserted-by":"crossref","first-page":"4002","DOI":"10.1182\/blood-2009-07-143545","article-title":"How I treat EBV lympho-proliferation","volume":"114","author":"Heslop","year":"2009","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.bbmt.2020.01.013_bib0038","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.bbmt.2009.06.019","article-title":"Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective","volume":"15","author":"Tomblyn","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"10.1016\/j.bbmt.2020.01.013_bib0039","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1200\/JCO.2012.45.8661","article-title":"Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline","volume":"31","author":"Flowers","year":"2013","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.bbmt.2020.01.013_bib0040","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1093\/cid\/cir073","article-title":"Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by Infectious Disease Society of America","volume":"52","author":"Freifeld","year":"2011","journal-title":"Clin Infect Dis"},{"issue":"11","key":"10.1016\/j.bbmt.2020.01.013_bib0041","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.6004\/jnccn.2012.0146","article-title":"Prevention and treatment of cancer-related infections","volume":"10","author":"Baden","year":"2012","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.bbmt.2020.01.013_bib0042","unstructured":"EBMT handbook 2008, revised edition 2012. https:\/\/www.ebmt.org\/education\/ebmt-handbook"},{"key":"10.1016\/j.bbmt.2020.01.013_bib0043","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the sub-distribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"issue":"23","key":"10.1016\/j.bbmt.2020.01.013_bib0044","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1182\/blood-2014-01-552984","article-title":"Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation","volume":"123","author":"Armand","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.01.013_bib0045","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1399-3062.2005.00088.x","article-title":"Pre- and post-engraftment bloodstream infection rates and associated mortality in allogeneic hematopoietic stem cell transplant recipients","volume":"7","author":"Almyroudis","year":"2005","journal-title":"Transpl Infect Dis"},{"issue":"1","key":"10.1016\/j.bbmt.2020.01.013_bib0046","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbmt.2017.08.024","article-title":"Pre-engraftment bloodstream infections after allogeneic hematopoietic cell transplantation: the impact of T-repleted transplant from haploidentical donors","volume":"24","author":"Mikulska","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.01.013_bib0047","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1093\/cid\/cix690","article-title":"Incidence, risk factors and outcome of pre-engraftment Gram-negative bacteremia after allogenic and autologous hematopoietic stem cell transplantation: an Italian prospective multicenter survey","volume":"65","author":"Girmenia","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.bbmt.2020.01.013_bib0048","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.bbmt.2018.02.021","article-title":"Clinical impact of pre-transplant multidrug-resistant gram-negative colonization in autologous and allogeneic hematopoietic stem cell transplantation","volume":"24","author":"Forcina","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.01.013_bib0049","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1093\/cid\/cix646","article-title":"Antimicrobial resistance in Gram-negative rods causing bacteremia in hematopoietic stem cell transplant recipients: intercontinental prospective study of the Infectious Diseases Working Party of the European Bone Marrow Transplantation group","volume":"65","author":"Averbuch","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.bbmt.2020.01.013_bib0050","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/bmt.2016.234","article-title":"Control of infectious mortality due to carbapenemase-producing Klebsiella pneumoniae in hematopoietic stem cell transplantation","volume":"52","author":"Forcina","year":"2017","journal-title":"Bone Marrow Transplantation"},{"issue":"12","key":"10.1016\/j.bbmt.2020.01.013_bib0051","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1182\/blood.V98.12.3456","article-title":"Durable engraftment of major histocompatibility complex-incompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and posttransplantation cyclophosphamide","volume":"98","author":"Luznik","year":"2001","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.bbmt.2020.01.013_bib0052","doi-asserted-by":"crossref","first-page":"2885","DOI":"10.1111\/ajt.14754","article-title":"Sirolimus exposure and the occurrence of cytomegalovirus DNAemia after allogeneic hematopoietic stem cell transplantation","volume":"18","author":"Pi\u00f1ana","year":"2018","journal-title":"Am J Transplant"},{"issue":"1","key":"10.1016\/j.bbmt.2020.01.013_bib0053","first-page":"78","article-title":"Risk factors for the development of cytomegalovirus disease after allogeneic stem cell transplantation","volume":"91","author":"Ljungman","year":"2006","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.bbmt.2020.01.013_bib0054","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1093\/cid\/ciu364","article-title":"Donor cytomegalovirus status influences the outcome of allogeneic stem cell transplant: a study by the European group for blood and marrow transplantation","volume":"59","author":"Ljungman","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.bbmt.2020.01.013_bib0055","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.bbmt.2018.01.013","article-title":"Selecting the best donor for haploidentical transplant: impact of HLA, killer cell immunoglobulin-like receptor genotyping, and other clinical variables","volume":"24","author":"Solomon","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"10.1016\/j.bbmt.2020.01.013_bib0056","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/s41409-017-0016-1","article-title":"Comparable survival using a CMV-matched or a mismatched donor for CMV+ patients undergoing T-replete haplo-HSCT with PT-Cy for acute leukemia: a study of behalf of the infectious diseases and acute leukemia working parties of the EBMT","volume":"53","author":"Cesaro","year":"2018","journal-title":"Bone Marrow Transplantation"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879120300458?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879120300458?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:10:29Z","timestamp":1761059429000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879120300458"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":56,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["S1083879120300458"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2020.01.013","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Infections after Allogenic Transplant with Post-Transplant Cyclophosphamide: Impact of Donor HLA Matching","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2020.01.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}